Martin Münchbach
Managing Director @ BB Biotech Ventures
Martin Münchbach is a Series A investor at BB Biotech Ventures focused on Biotechnology and Medical. Martin is a founding partner of Pureos and has been a venture capital investor since 1999, investing in life science companies across all stages and types. Prior to Pureos, he was senior investment advisor private equity at Bellevue Asset Management. Martin’s most successful investments and board assignments include Radius Health, MolecularPartners, Optimer, Axovan and Glycart. Martin is currently a BoD member at Ypsomed Holding, Alentis Therapeutics, binX Health, River Renal and SatoSea Oncology. Martin obtained his PhD in protein chemistry from the ETH Zurich and his MAS in Management, Technology, and Economics from ETH Zurich.
- Total investments:
- 12
- Last investment:
- Lead investor:
- 8%
Last updated:
For AI agents: llms.txt
Industries Martin Münchbach invests in
Stages Martin Münchbach invests in
Countries Martin Münchbach invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 4 (33%)
- Medical 3 (25%)
- Pharmaceutical 3 (25%)
- Health Care 2 (17%)
- Therapeutics 2 (17%)
Stage
- Series A 3 (25%)
- Series B 2 (17%)
- Series C 2 (17%)
- Funding Round 1 (8%)
- Private Equity 1 (8%)
Country
- United States 3 (25%)
- Germany 1 (8%)
- Switzerland 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Ariceum Therapeutics focuses on diagnosis and precision treatment of neuroendocrine and certain other aggressive, hard-to-treat cancers. | $25M / Series A / Apr 18, 2023 | ||
| Ariceum Therapeutics focuses on diagnosis and precision treatment of neuroendocrine and certain other aggressive, hard-to-treat cancers. | $26.8M / Series A / Jun 08, 2022 | ||
| Radius is a leading company in the discovery and development of a new generation of drug therapies for osteoporosis and women's health.The company's first drug in clinical trials is designed to build new bone in patients with osteoporosis, with the goal of reducing the risk of future fractures and improving the quality of life.Their long-term focus is on additional areas in women's health that include symptoms of menopause, reproductive disorders, and frailty associated with aging.Radius's scientific leadership includes some of the world's leading researchers in the fields of bone metabolism, endocrinology, and medicinal chemistry, and the company has a broad foundation in nuclear hormone receptors. | $43M / Private Equity / Apr 25, 2013 | ||
| Radius is a leading company in the discovery and development of a new generation of drug therapies for osteoporosis and women's health.The company's first drug in clinical trials is designed to build new bone in patients with osteoporosis, with the goal of reducing the risk of future fractures and improving the quality of life.Their long-term focus is on additional areas in women's health that include symptoms of menopause, reproductive disorders, and frailty associated with aging.Radius's scientific leadership includes some of the world's leading researchers in the fields of bone metabolism, endocrinology, and medicinal chemistry, and the company has a broad foundation in nuclear hormone receptors. | $21.4M / Private Equity / Dec 16, 2011 | ||
| Radius is a leading company in the discovery and development of a new generation of drug therapies for osteoporosis and women's health.The company's first drug in clinical trials is designed to build new bone in patients with osteoporosis, with the goal of reducing the risk of future fractures and improving the quality of life.Their long-term focus is on additional areas in women's health that include symptoms of menopause, reproductive disorders, and frailty associated with aging.Radius's scientific leadership includes some of the world's leading researchers in the fields of bone metabolism, endocrinology, and medicinal chemistry, and the company has a broad foundation in nuclear hormone receptors. | $66M / Series C / Jul 26, 2011 | ||
| Tioga Pharmaceuticals, Inc. develops therapies for the treatment of gastrointestinal diseases. Its product includes asimadoline, an orally administered small molecule therapeutic for the treatment of irritable bowel syndrome and functional dyspepsia. The company was founded in 2005 and is based in San Diego, California. | $18M / Feb 17, 2010 | ||
| Molecular Partners is a clinical-stage biopharmaceutical company working to advance modern medicine and significantly improve the management of serious diseases. They are developing a powerful new class of potent, specific and versatile small protein therapies called DARPin® therapeutics. | $44.2M / Series B / Dec 16, 2009 | ||
| Radius is a leading company in the discovery and development of a new generation of drug therapies for osteoporosis and women's health.The company's first drug in clinical trials is designed to build new bone in patients with osteoporosis, with the goal of reducing the risk of future fractures and improving the quality of life.Their long-term focus is on additional areas in women's health that include symptoms of menopause, reproductive disorders, and frailty associated with aging.Radius's scientific leadership includes some of the world's leading researchers in the fields of bone metabolism, endocrinology, and medicinal chemistry, and the company has a broad foundation in nuclear hormone receptors. | $15M / Series C / Nov 20, 2008 | ||
| BioVascular is a clinical stage privately held biotechnology company developing “first in class†products for platelet mediated cardiovascular diseases.BioVascular’s initial product, saratin, is a polypeptide produced by recombinant means in yeast. This product was discovered by and licensed from Merck KGaA. BioVascular is conductinghuman clinical trials of saratin for use in hemodialysis access graft and peripheral artery grafts to reduce intimal hyperplasia, which can lead to failure of the graft. | $10.9M / Series C / Feb 07, 2008 | ||
| Molecular Partners is a clinical-stage biopharmaceutical company working to advance modern medicine and significantly improve the management of serious diseases. They are developing a powerful new class of potent, specific and versatile small protein therapies called DARPin® therapeutics. | $15.6M / Series A / Aug 14, 2007 | ||
| See all 12 investments → | |||
Co-Investors
About BB Biotech Ventures
BB BIOTECH VENTURES is a healthcare-dedicated venture capital fund, focused on companies that develop and market drugs and medical devices. The Guernsey–based fund is advised by the Bellevue Asset Management Group, which has operations in Curaçao, Boston/USA and Kusnacht/Zurich, Switzerland. BB BIOTECH VENTURES has a dedicated teamof investment advisors and an advisory board. In addition, it is supported by all of the Group’s health care investment experts, and an extensive network of specialists and advisors. Our goal is to maximize the returns to our investors. To achieve this goal, we combine hard working, experience, networking, and focus on value creation.
BB Biotech Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Martin Münchbach
Managing Director
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Martin Münchbach invest in?
Martin Münchbach invests primarily in Biotechnology, Medical and Pharmaceutical startups, most often at Series A and Series B stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Martin Münchbach?
Public channels for Martin Münchbach include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Martin Münchbach last invest?
The most recent investment recorded for Martin Münchbach closed in Apr 2023. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
